New Genomic Profiling Kit May Provide More Accessible Testing and Personalized Care to Patients with Cancer

Article

The AVENIO Tumor Tissue Comprehensive Genomic Profiling Kit could allow for more accessible genetic testing and result in more personalized treatments.

The launch of the AVENIO Tumor Tissue Comprehensive Genomic Profiling (CGP) Kit could bring a more personalized medicine approach to patients with cancer by making genetic testing more readily accessible, according to a press release from the developer, Roche.

A future iteration of the kit, which complements currently the CGP portfolio at Roche, may bring additional resources to clinicians to help them diagnose and treat cancer, as well as presently enabling laboratories to further expand their oncology research efforts in house. Deviating from the results garnered from smaller panels including hotspot and single gene tests, CGP testing offers comprehensive information in a single test on complex genomic information on tumor mutational burden, microsatellite instability, and loss of heterozygosity.

“To treat cancer effectively, we must understand what drives it at a molecular level. CGP helps inform decisions about available treatment options, including targeted therapies, immunotherapies, tumor-agnostic treatments and clinical trial participation, based on the unique genomic profile of a patient’s tumor,” Thomas Schinecker, chief executive officer at Roche Diagnostics, said in a press release.

The kit is a research use only, next generation sequencing test can offer an end-to-end workflow from DNA extraction and library preparation to a generation of variant results obtained via the FoundationOne Analysis platform. The gene panel was based on the FoundationOne platform, which was designed to match the FoundationOne CDx panel in order to assess 324 cancer related genes in 4 main classes of genomic alterations and genomic signatures that have been known to result in cancer.

Every kit can run 24 samples and can be completed within 5 days from DNA isolation to variant results. The AVENIO CPG kit runs on Illumina IVD systems’ NextSeq 500/550 RUO, as well as NextSeq 550 Dx System in research mode. The 2 companies entered into an agreement in January 2020 to develop, produce, and commercialize AVENIO tests for both tissue and blood utilizing Illumina’s IVD systems.

The kit will launch in multiple regions across the world, and Roche is planning to add additional solutions to the portfolio.

“The launch of this kit will significantly expand access to genomic profiling globally by providing an in-house solution for those who cannot otherwise access our portfolio of tests through our centralised laboratories,” Brian Alexander, chief executive officer at Foundation Medicine, said in a press release.

Reference

Roche launches comprehensive genomic profiling kit to expand access to personalised cancer research. News Release. Roche. October 25, 2021. Accessed October 28, 2021. https://bit.ly/3CseK1Q

Related Videos
Cancer vaccines are a “cross-cutting approach” that may be applicable across several cancer types, according to Catherine J. Wu, MD.
mRNA may be a potential modality for developing cancer-based vaccines, according to Catherine J. Wu, MD.
Analyzing the KRAS mutation across various cancer types may be a worthwhile target when using a cancer vaccine or immunotherapy, says Catherine J. Wu, MD.
The AACR Health Disparities Report highlights the changes needed to achieve health equity for patients with cancer.
Robert A. Winn, MD, gives insight into how institutions and community practices can improve access to cancer care.
In the October edition of Snap Recap, we review the latest FDA news and the vote from the last ODAC meeting.
In this September edition of Snap Recap, we share our highlights from Prostate Cancer Awareness Month, news in the breast cancer space, and the latest FDA updates.
Implementing tax benefits for manufacturers who produce chemotherapy drugs may be one solution to increase drug production in the United States, according to Lucio N. Gordan, MD.
Lucio N. Gordan, MD, describes how his practice deals with increasing costs of limited chemotherapy agents to ensure that patients with cancer continue to receive treatment.